Most read article(s)

Open Access
The Pharmacological Case for Cannabigerol
Rahul Nachnani, Wesley M. Raup-Konsavage and Kent E. Vrana

Journal of Pharmacology and Experimental Therapeutics February 2021, 376 (2) 204-212; DOI: https://doi.org/10.1124/jpet.120.000340
You have access
Ocular Drug Delivery: Present Innovations and Future Challenges
Vrinda Gote, Sadia Sikder, Jeff Sicotte and Dhananjay Pal

Journal of Pharmacology and Experimental Therapeutics September 2019, 370 (3) 602-624; DOI: https://doi.org/10.1124/jpet.119.256933
You have access
Targeting the Myofibroblast Genetic Switch: Inhibitors of Myocardin-Related Transcription Factor/Serum Response Factor–Regulated Gene Transcription Prevent Fibrosis in a Murine Model of Skin Injury
Andrew J. Haak, Pei-Suen Tsou, Mohammad A. Amin, Jeffrey H. Ruth, Phillip Campbell, David A. Fox, Dinesh Khanna, Scott D. Larsen and Richard R. Neubig

Journal of Pharmacology and Experimental Therapeutics June 2014, 349 (3) 480-486; DOI: https://doi.org/10.1124/jpet.114.213520
Open Access
Nose-to-Brain Delivery
Zian Wang, Guojun Xiong, Wai Chun Tsang, Andreas G. Schätzlein and Ijeoma F. Uchegbu

Journal of Pharmacology and Experimental Therapeutics September 2019, 370 (3) 593-601; DOI: https://doi.org/10.1124/jpet.119.258152
Open Access
Stem Cell Therapies in Alzheimer’s Disease: Applications for Disease Modeling
Zizhen Si and Xidi Wang

Journal of Pharmacology and Experimental Therapeutics May 2021, 377 (2) 207-217; DOI: https://doi.org/10.1124/jpet.120.000324
Open Access
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease
Patricia Schroeder, Keertik Fulzele, Sanjeev Forsyth, Maria D. Ribadeneira, Sylvie Guichard, Erik Wilker, C. Gary Marshall, Adam Drake, Rose Fessler, Diamantis G. Konstantinidis, Katie G. Seu and Theodosia A. Kalfa

Journal of Pharmacology and Experimental Therapeutics March 2022, 380 (3) 210-219; DOI: https://doi.org/10.1124/jpet.121.000743
Open Access
A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson’s Disease
David H. Margolin, Nicola L. Brice, Antonia M. Davidson, Kim L. Matthews and Mark B. L. Carlton

Journal of Pharmacology and Experimental Therapeutics April 2022, 381 (1) 33-41; DOI: https://doi.org/10.1124/jpet.121.000842
Open Access
SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D₂ Receptor Mechanism of Action
Nina Dedic, Philip G. Jones, Seth C. Hopkins, Robert Lew, Liming Shao, John E. Campbell, Kerry L. Spear, Thomas H. Large, Una C. Campbell, Taleen Hanania, Emer Leahy and Kenneth S. Koblan

Journal of Pharmacology and Experimental Therapeutics October 2019, 371 (1) 1-14; DOI: https://doi.org/10.1124/jpet.119.260281
You have access
Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis
Stefania Petrosino, Roberta Verde, Massimo Vaia, Marco Allarà, Teresa Iuvone and Vincenzo Di Marzo

Journal of Pharmacology and Experimental Therapeutics June 2018, 365 (3) 652-663; DOI: https://doi.org/10.1124/jpet.117.244368
Open Access
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf, Todd Covey, Raquel Izumi, Bas van de Kar, Michael Gulrajani, Bart van Lith, Maaike van Hoek, Edwin de Zwart, Diana Mittag, Dennis Demont, Saskia Verkaik, Fanny Krantz, Paul G. Pearson, Roger Ulrich and Allard Kaptein

Journal of Pharmacology and Experimental Therapeutics November 2017, 363 (2) 240-252; DOI: https://doi.org/10.1124/jpet.117.242909

Main menu

User menu

Search

Most read article(s)

Pages

Navigate

More Information

ASPET's Other Journals